Dennis A Ausiello sold $14M of ALNY
director at ALNYLAM PHARMACEUTICALS, INC.. 31,448 shares at an average of $436.58, traded Aug 14, 2025, filed Aug 15, 2025.
Score components
- +15RoleDirector
- +25Trade size$13.7M at market
- +20Share of holdings soldSold 97% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000079, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2025 | MOption exercise Common Stock10b5-1 | +9,000 | $72.01 | $648k | 9,911 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Common Stock10b5-1 | +5,153 | $128.31 | $661k | 15,064 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Common Stock10b5-1 | +4,581 | $148.77 | $682k | 19,645 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Common Stock10b5-1 | +5,228 | $151.22 | $791k | 24,873 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Common Stock10b5-1 | +4,032 | $171.95 | $693k | 28,905 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Common Stock10b5-1 | +3,454 | $189.87 | $656k | 32,359 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -1,985 | $430.81 | $855k | 30,374 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -1,938 | $432.94 | $839k | 28,436 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -2,098 | $434.50 | $912k | 26,338 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -7,675 | $435.40 | $3.3M | 18,663 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -5,358 | $436.00 | $2.3M | 13,305 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -1,922 | $437.56 | $841k | 11,383 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -2,086 | $438.34 | $914k | 9,297 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -5,302 | $439.27 | $2.3M | 3,995 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -1,238 | $440.54 | $545k | 2,757 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -1,205 | $441.88 | $532k | 1,552 | Aug 15, 2025 |
| Aug 14, 2025 | SOpen-market sale Common Stock10b5-1 | -641 | $442.66 | $284k | 911 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -9,000 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,153 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,581 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,228 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,032 | $0.00 | $0 | 0 | Aug 15, 2025 |
| Aug 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,454 | $0.00 | $0 | 0 | Aug 15, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 3,250 shares | -13% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.1M 3,492 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.